PFE - This weight loss stock is the best alternative to Eli Lilly Novo - SA Sentiment
2024-07-12 04:12:28 ET
More on Amgen
- Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade)
- Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
- Amgen: You Haven't Seen Anything Yet
- Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
- FDA grants expanded approval for Amgen's Blincyto in ALL